Subtype
Malignant Neoplasm of Unknown Primary
CI-CAN-00001150CUPExplore in graph →
4,163 active trials54 approved drugs532 evidence items
- NCIt
- C8566
- Other
- 1 more code
Loading cancer entity…
Subtype
CI-CAN-00001150CUPExplore in graph →
Clinical trials
14,260 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,895)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07217171 | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas | recruiting | Phase 1 | 160 | EvolveImmune United, IncINDUSTRY | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07255001 | Using Strength Tests to Better Understand How Pancreatic Cancer Affects Muscle Mass and Quality of Life(PanFit) | recruiting | N/A | 50 | British Columbia Cancer AgencyOTHER | 1 | Sep 15, 2026 |
| clinicaltrials |
| NCT07341737 | SL-28 for Advanced Solid Tumours | recruiting | Phase 1 / Phase 2 | 60 | Second Life TherapeuticsINDUSTRY | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07429487 | Assessment of Adherence to Remotely Monitored Physical Activity Tracked on a Smartwatch, and Its Impact on Reducing Fatigue 3 Months After Adjuvant Chemotherapy for Cancer(WATCH AND ACT) | recruiting | N/A | 98 | Centre Antoine LacassagneOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07513311 | A Nurse-Led, Coping and Supportive Intervention for Patients With Triple-Negative Breast Cancer(RESTORE) | recruiting | N/A | 75 | Massachusetts General HospitalOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07630168 | Effects of Infusion Timing on Treatment Response in Solid Tumors(TIMED) | recruiting | Phase 2 | 238 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07702292 | [68Ga]BED003 PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications | recruiting | Phase 2 | 71 | Blue Earth DiagnosticsINDUSTRY | 2 | Sep 15, 2026 | clinicaltrials |
| NCT07776080 | Iparomlimab and Tuvonralimab With Lenvatinib, Radiotherapy, and HAIC for Hepatocellular Carcinoma With Portal Vein Tumor Thrombus | recruiting | Phase 2 | 35 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07796880 | Neoadjuvant Culmerciclib Combined With Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer | recruiting | Phase 2 | 80 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT02734537 | Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery | recruiting | Phase 2 | 189 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Sep 14, 2026 | clinicaltrials |
| NCT04380545 | Nivolumab, Fluorouracil, and Interferon Alpha 2B for the Treatment of Unresectable Fibrolamellar Cancer | recruiting | Phase 1 / Phase 2 | 15 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT04575935 | Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial | recruiting | Phase 3 | 580 | M.D. Anderson Cancer CenterOTHER | 5 | Sep 14, 2026 | clinicaltrials |
| NCT04723095 | Establishing a Tumor Registry for Patients With Neuroendocrine Carcinoma of the Cervix(NeCTuR) | recruiting | — | 750 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT04977453 | GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 317 | GI Innovation, Inc.INDUSTRY | 2 | Sep 14, 2026 | clinicaltrials |
| NCT05059444 | ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation(ORACLE) | recruiting | — | 2,285 | Guardant Health, Inc.INDUSTRY | 5 | Sep 14, 2026 | clinicaltrials |
| NCT05482516 | Evaluating Novel Therapies in ctDNA Positive GI Cancers(MRD-GI) | recruiting | Phase 3 | 20 | Georgetown UniversityOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT05752149 | Fluorescence-guided Surgery in Laryngeal- and Hypopharyngeal Cancer: a Feasibility Trial(STELLAR) | recruiting | Phase 2 | 27 | Erasmus Medical CenterOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT06246968 | A Study of Pembrolizumab and Ablation (Cryoablation or Histotripsy) in People With Breast Cancer | recruiting | Phase 1 | 30 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT06732388 | Itraconazole in Combination With Ablation for the Prevention of Esophageal Cancer in Patients With High-risk Barrett's Esophagus | recruiting | Phase 2 | 76 | National Cancer Institute (NCI)NIH | 1 | Sep 14, 2026 | clinicaltrials |
| NCT06789198 | Peptide Vaccine for Fibrolamellar Hepatocellular Carcinoma Patients and Other Tumor Entities Carrying the Driver Fusion DNAJB1-PRKACA(FusionVAC22_02) | recruiting | Phase 1 | 20 | University Hospital TuebingenOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT07020806 | [68Ga]Ga DOTA-5G as a Diagnostic Imaging Agent for Metastatic/Advanced Invasive Lobular Breast Cancer (LBC) | recruiting | Phase 1 | 30 | University of California, DavisOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT07113691 | Iadademstat + SBRT With Atezo in ES-SCLC(TIARA) | recruiting | Phase 1 | 15 | Yale UniversityOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT07218146 | A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)(DLLEVATE) | recruiting | Phase 3 | 480 | Zai Lab (Shanghai) Co., Ltd.INDUSTRY | 15 | Sep 14, 2026 | clinicaltrials |
| NCT07325136 | A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination Therapy in Participants With Relapsed/Refractory Small Cell Lung Cancer | recruiting | Phase 1 / Phase 2 | 240 | Bristol-Myers SquibbINDUSTRY | 6 | Sep 14, 2026 | clinicaltrials |
| NCT07391956 | Tier Palliative Care For Patients With Advanced Heart Failure or Cancer(TIER-PC) | recruiting | N/A | 400 | Icahn School of Medicine at Mount SinaiOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT07513389 | Omission of Postoperative Radiation in HPV-Associated Oropharyngeal Cancer Using ctHPVDNA Surveillance (OPERATION) | recruiting | Phase 2 | 36 | Medical University of South CarolinaOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT07516366 | Testing the Safety and Feasibility of Immunotherapy Drugs, Botensilimab and Balstilimab, Before Surgery for Clear Cell Renal Cell Carcinoma, NEO RoBOT Trial | recruiting | Phase 2 | 16 | National Cancer Institute (NCI)NIH | 1 | Sep 14, 2026 | clinicaltrials |
| NCT07615374 | Laparoscopic-endoscopic Surgery Assisted Sentinel Lymph Node Navigation Surgery for Early Gastric Cancer | recruiting | N/A | 36 | Jilin UniversityOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT07772869 | Uterine Lavage to Detect Ovarian Cancer Risk | recruiting | N/A | 75 | University of WashingtonOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT07818018 | A Study of 2141-V11 in People With Esophageal, Gastric, or Gastroesophageal Junction Adenocarcinoma | recruiting | Phase 1 / Phase 2 | 30 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT04633239 | Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer | recruiting | Phase 1 | 42 | National Cancer Institute (NCI)NIH | 1 | Sep 11, 2026 | clinicaltrials |
| NCT05306041 | Neoadjuvant Endocrine Therapy +/- the PI3K Inhibitor Inavolisib in HER2+, HR+, PIK3CA Mutant Early Breast Cancer(GeparPiPPa) | recruiting | Phase 2 | 170 | GBG Forschungs GmbHOTHER | 6 | Sep 11, 2026 | clinicaltrials |
| NCT05365581 | A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer | recruiting | Phase 1 | 398 | Astellas Pharma Global Development, Inc.INDUSTRY | 8 | Sep 11, 2026 | clinicaltrials |
| NCT05753748 | Surveillance vs. Endoscopic Therapy for Barrett's Esophagus With Low-grade Dysplasia(SURVENT) | recruiting | N/A | 680 | University of Colorado, DenverOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT06309485 | Phase 2 Study of WGI-0301 for Advanced HCC | recruiting | Phase 2 | 60 | Zhejiang Haichang Biotech Co., Ltd.INDUSTRY | 2 | Sep 11, 2026 | clinicaltrials |
| NCT06487403 | HN-BIO 02: A Phase II Randomized Study of the Effects of Delayed Elective Radiotherapy on Head and Neck MRI and Immune Response Biomarkers(HN-Bio 02) | recruiting | N/A | 40 | University Health Network, TorontoOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT06657222 | First in Human Study of TUB-030 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 250 | Tubulis GmbHINDUSTRY | 5 | Sep 11, 2026 | clinicaltrials |
| NCT06764875 | A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer | recruiting | Phase 3 | 840 | AstraZenecaINDUSTRY | 28 | Sep 11, 2026 | clinicaltrials |
| NCT06784752 | Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET(NETTER-3) | recruiting | Phase 3 | 240 | Novartis PharmaceuticalsINDUSTRY | 12 | Sep 11, 2026 | clinicaltrials |
| NCT07081360 | Neoadjuvant vs Upfront Surgery for Resectable Pancreatic Cancer and Periampullary Cancer | recruiting | Phase 3 | 262 | Minia UniversityOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT07132541 | Saleh's Technique for Pancreaticojejunostomy (Pancreatic Parenchymal Injection of N-butyl-2-cyanoacrylate)(NBCA) | recruiting | Phase 1 | 30 | Minia UniversityOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT07148830 | Mesopancreatic Excision for Pancreatic Duct Adenocarcinoma.(TMpE) | recruiting | N/A | 100 | Minia UniversityOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT07161388 | Durvalumab Consolidation After Chemoradiation Therapy for Limited Stage SCLC in China(DREAM) | recruiting | — | 200 | AstraZenecaINDUSTRY | 1 | Sep 11, 2026 | clinicaltrials |
| NCT07564401 | A Study to Evaluate DJI136, a DLL3-targeted CAR-T Therapy | recruiting | Phase 1 / Phase 2 | 80 | Novartis PharmaceuticalsINDUSTRY | 4 | Sep 11, 2026 | clinicaltrials |
| NCT07673887 | A Study of ASP2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric Cancer | recruiting | Phase 3 | 570 | Astellas Pharma Global Development, Inc.INDUSTRY | 3 | Sep 11, 2026 | clinicaltrials |
| NCT07714538 | Breath Research Narrow Validation for Gastrointestinal Cancer Detection(BRAVE) | recruiting | — | 1,000 | Imperial College LondonOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT07815223 | A Phase II Study of Tislelizumab Plus Anlotinib Consolidation After Chemoradiotherapy in LS-SCLC | recruiting | Phase 2 | 20 | Yantai Yuhuangding HospitalOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT04864054 | GPC3-Targeted T-Cell Therapy (ECT204) in Adults With Advanced HCC(ARYA-3) | recruiting | Phase 1 / Phase 2 | 60 | Eureka Therapeutics Inc.INDUSTRY | 2 | Sep 10, 2026 | clinicaltrials |
Data updated 15 days agoSource updated Sep 15, 2026source: clinicaltrials